These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 514121)

  • 1. Cellular control of heparin in blood.
    Mahadoo J; Jaques LB
    Med Hypotheses; 1979 Aug; 5(8):835-41. PubMed ID: 514121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of protamine of the prolonged response to intrapulmonary heparin.
    Wright CJ; Mahadoo J; Jaques LB
    Can J Surg; 1981 Mar; 24(2):130-2. PubMed ID: 7225967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma heparin levels after administration of calcium and sodium salts of heparin.
    Thomas DP; Sagar S; Stamatakis JD; Maffei FH; Erdi A; Kakkar VV
    Thromb Res; 1976 Sep; 9(3):241-8. PubMed ID: 790636
    [No Abstract]   [Full Text] [Related]  

  • 4. Kinetics of heparin administration.
    Perry MO; Horton J
    Arch Surg; 1976 Apr; 111(4):403-9. PubMed ID: 1259578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of heparin after a single intravenous or subcutaneous injection].
    Mombelli G; Schaedelin J; Beck EA
    Schweiz Med Wochenschr; 1977 Jun; 107(23):810-5. PubMed ID: 877532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The heparin target organ--the endothelium. Studies in a rat model.
    Hiebert LM; Wice SM; McDuffie NM; Jaques LB
    Q J Med; 1993 May; 86(5):341-8. PubMed ID: 8327652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity].
    Jacobs C; Grebe S; Kietzmann M; Mischke R
    Dtsch Tierarztl Wochenschr; 1999 Nov; 106(11):478-81. PubMed ID: 10609418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers.
    Lockner D; Bratt G; Törnebohm E; Aberg W
    Haemostasis; 1986; 16 Suppl 2():8-10. PubMed ID: 3744135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
    Wilkerson RD; Conran PB; Greene SL
    Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Volume of distribution and half-life of heparin after intravenous administration].
    Zöllner N; Kaiser W
    Res Exp Med (Berl); 1972; 158(2):89-94. PubMed ID: 4561302
    [No Abstract]   [Full Text] [Related]  

  • 11. A train difference in anticoagulant response to subcutaneous administration of heparin in mice.
    Sue TK; Jaques LB; Yelland J
    Thromb Res; 1978 Jan; 12(1):5-13. PubMed ID: 644560
    [No Abstract]   [Full Text] [Related]  

  • 12. The observation of heparin on endothelium after injection.
    Hiebert LM; Jaques LB
    Thromb Res; 1976 Feb; 8(2):195-204. PubMed ID: 1251350
    [No Abstract]   [Full Text] [Related]  

  • 13. Intrapulmonary heparin. A new procedure for anticoagulant therapy.
    Jaques LB; Mahadoo J; Kavanagh LW
    Lancet; 1976 Nov; 2(7996):1157-61. PubMed ID: 62993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appearance of heparin antithrombin-active chains in vivo after injection of commercial heparin and in anaphylaxis.
    Levy SW; Jaques LB
    Thromb Res; 1978 Sep; 13(3):429-41. PubMed ID: 741437
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of various doses and various applications of heparin on the fat metabolism and on blood coagulation.
    Losonczy H; Nagy I
    Wien Klin Wochenschr; 1984 Dec; 96(24):885-9. PubMed ID: 6528619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heparin-mobilisable pool of platelet factor 4: a comparison of intravenous and subcutaneous heparin and Kabi heparin fragment 2165.
    O'Brien JR; Etherington MD; Pashley MA
    Thromb Haemost; 1985 Dec; 54(4):735-8. PubMed ID: 4089807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of prolonged hypocoagulation appearing after intratracheal administration of heparin].
    Efimov VS; Rumiantseva AG; Golovleva OA; Rozkin MIa
    Biull Eksp Biol Med; 1992 May; 113(5):509-12. PubMed ID: 1421273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of heparin. I. Studies of dose dependence in rats.
    Bjornsson TD; Levy G
    J Pharmacol Exp Ther; 1979 Aug; 210(2):237-42. PubMed ID: 458630
    [No Abstract]   [Full Text] [Related]  

  • 20. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
    Hoppensteadt DA; Walenga JM; Fasanella A; Jeske W; Fareed J
    Thromb Res; 1995 Jan; 77(2):175-85. PubMed ID: 7740509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.